Mount Sinai Hospital changes its name to the “Mount Sinai Fuster Heart Hospital” in honour of Dr Fuster

Mount Sinai Hospital  has changed the name of its Cardiovascular Hospital, which will now be called the “Mount Sinai Fuster Heart Hospital“ in honour of Dr Valentín Fuster,  General Director of the Spanish National Centre for Cardiovascular Research  (CNIC).

The change of name comes in recognition of Dr Fuster’s profound impact not only on the field of cardiology, but also for his leadership at Mount Sinai.

“I am grateful for this honour and proud of my life’s work at Mount Sinai,” said Dr Fuster. “I can think of nothing more fulfilling than contributing to the understanding, prevention, and treatment of cardiovascular disease, the No.1 killer worldwide”.

Dr Fuster came up with the idea for the cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research (CNIC) and Ferrer, a single pill incorporating three drugs that are normally taken separately, which is effective in the prevention of secondary adverse cardiovascular events in people who have previously suffered a heart attack. Dr Fuster and his team demonstrated that the polypill reduces cardiovascular death in 33% of the population. Recently, the World Health Organisation (WHO) included this medication in its List of Essential Medicines. The strategy is endorsed by the results of the SECURE study, published in August 2022 by the New England Journal of Medicine (NEJM).

Polipíldora CNIC-Ferrer

Dr Fuster has spent decades devoted to the research of biological, socio-economic and environmental mechanisms that affect heart diseases. He also leads a specialised educational health initiative in schools of Harlem and other areas of New York to study the most effective ways of instilling healthy habits in children from an early age and thus reducing risk factors and preventable heart diseases in the next generation.

“Dr. Fuster’s dedication to interdisciplinary translational research has defined Mount Sinai’s world-class reputation in cardiovascular care. His ground-breaking contributions to the field have transformed the nature of care for patients.  His legacy is one to sustain and emulate at any innovative institution. It is our privilege to have him as our premier ambassador, now and forever,” affirms Dennis S. Charney, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai.